Equities Analysts Offer Predictions for NTLA FY2025 Earnings

Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) - Analysts at Chardan Capital reduced their FY2025 earnings estimates for Intellia Therapeutics in a research note issued to investors on Monday, November 18th. Chardan Capital analyst Y. Livshits now forecasts that the company will post earnings of ($4.14) per share for the year, down from their previous estimate of ($4.02). Chardan Capital currently has a "Buy" rating and a $91.00 target price on the stock. The consensus estimate for Intellia Therapeutics' current full-year earnings is ($5.13) per share.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($1.34) EPS for the quarter, beating the consensus estimate of ($1.37) by $0.03. The firm had revenue of $9.10 million for the quarter, compared to analysts' expectations of $8.28 million. During the same quarter in the prior year, the business posted ($1.38) EPS. The business's quarterly revenue was down 24.1% on a year-over-year basis.

Several other analysts have also recently issued reports on the company. Canaccord Genuity Group reaffirmed a "buy" rating and set a $90.00 target price on shares of Intellia Therapeutics in a research report on Tuesday. The Goldman Sachs Group reduced their target price on shares of Intellia Therapeutics from $31.00 to $20.00 and set a "neutral" rating for the company in a report on Friday, October 25th. StockNews.com upgraded shares of Intellia Therapeutics to a "sell" rating in a report on Friday, November 8th. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $54.00 price objective on shares of Intellia Therapeutics in a research report on Thursday, September 19th. Finally, Robert W. Baird decreased their target price on shares of Intellia Therapeutics from $24.00 to $18.00 and set a "neutral" rating for the company in a research report on Friday, October 25th. One investment analyst has rated the stock with a sell rating, six have given a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $54.94.

Intellia Therapeutics Stock Performance

NASDAQ:NTLA opened at $13.12 on Thursday. The firm has a 50-day simple moving average of $18.40 and a 200-day simple moving average of $21.91. Intellia Therapeutics has a one year low of $12.82 and a one year high of $34.87.

Insider Transactions at Intellia Therapeutics

In related news, CAO Michael P. Dube sold 2,012 shares of the company's stock in a transaction dated Wednesday, October 2nd. The stock was sold at an average price of $19.01, for a total value of $38,248.12. Following the completion of the transaction, the chief accounting officer now owns 47,012 shares of the company's stock, valued at approximately $893,698.12. This represents a 4.10 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 3.20% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in NTLA. Blue Trust Inc. lifted its holdings in Intellia Therapeutics by 1,664.3% during the second quarter. Blue Trust Inc. now owns 1,482 shares of the company's stock valued at $33,000 after purchasing an additional 1,398 shares in the last quarter. EverSource Wealth Advisors LLC boosted its stake in shares of Intellia Therapeutics by 763.5% in the second quarter. EverSource Wealth Advisors LLC now owns 1,753 shares of the company's stock worth $39,000 after acquiring an additional 1,550 shares during the last quarter. Eastern Bank purchased a new stake in shares of Intellia Therapeutics during the third quarter worth approximately $41,000. Values First Advisors Inc. purchased a new position in Intellia Therapeutics in the 3rd quarter valued at $54,000. Finally, First Horizon Advisors Inc. lifted its stake in shares of Intellia Therapeutics by 22.1% in the second quarter. First Horizon Advisors Inc. now owns 2,604 shares of the company's stock worth $58,000 after buying an additional 472 shares in the last quarter. Hedge funds and other institutional investors own 88.77% of the company's stock.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.